Myriad Genetics (MYGN) Net Cash Flow (2009 - 2026)

Myriad Genetics has disclosed Net Cash Flow across 18 years of filings, most recently posting -$25.2 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 129.09% year-over-year to -$25.2 million; the TTM figure through Mar 2026 stood at $24.4 million (up 642.22% YoY), while the FY2025 annual figure was $38.6 million, up 237.86% from the prior year.
• Net Cash Flow slipped to -$25.2 million in Q1 2026, from -$3.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for MYGN reached as high as $71.1 million in Q3 2025 and fell as low as -$92.6 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$3.6 million (2025), against an average of -$7.8 million.
• The widest YoY moves for Net Cash Flow: up 1294.12% in 2025, down 1178.57% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$45.0 million in 2022, then jumped by 222.67% to $55.2 million in 2023, then tumbled by 94.93% to $2.8 million in 2024, then tumbled by 228.57% to -$3.6 million in 2025, then sank by 600.0% to -$25.2 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$25.2 million, -$3.6 million, and $71.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.